Liquid biopsy company ANGLE (LON: AGL) has seen its shares jump at the open on Thursday after the University Hospital Ghent, Belgium, published research results undertaken in oesophageal cancer, using ANGLE's Parsortix system.
It is the first published result in this cancer type, and the Parsortix system has now been validated in 24 cancer types across 28 independent cancer research centres in 11 countries.
Researchers in the study used ANGLE's Parsortix system to isolate epithelial circulating tumour cells (CTCs) in patients and then performed cell-based image analysis to compare cell morphology and characteristics.
ANGLE said the study validated how the workstream could be utilised for downstream molecular analysis of cancer biomarkers from single CTCs in future research, which would enable individualised targeted therapy from a simple blood draw.
“The Parsortix system is ideally placed to isolate these clinically relevant cells as a size and deformability-based system which is marker independent,” stated ANGLE.
ANGLE Founder and CEO Andrew Newland commented: “Treatment selection for oesophageal cancer remains a major unmet medical need and we are pleased that this study demonstrates the promise of the Parsortix system in improving the outcomes for these patients.
“We believe that additional studies focused on clinically relevant mesenchymal CTCs, which can be captured and analysed using the Parsortix system, are urgently needed and we look forward to the Ghent team progressing their work in this hard-to-treat cancer type.”
ANGLE's share price opened up Thursday's session over 3% higher at 130p. It is currently priced at 129.75p.
Should you invest in ANGLE shares?
ANGLE shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are ANGLE shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies